サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1489259

ADHD（注意欠如・多動症）の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Attention Deficit Hyperactivity Disorder Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 174 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ADHD（注意欠如・多動症）の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年05月01日
発行: Value Market Research
ページ情報: 英文 174 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ADHD（注意欠如・多動症）市場の世界需要は、2023年の193億2,000万米ドルから2032年には約280億米ドルの市場規模に達すると推定され、調査期間2024-2032年のCAGRは4.21%です。

ADHD（注意欠如・多動症）は、多動性、不注意、衝動性の症状を特徴とする神経発達疾患であり、日常生活に支障をきたす可能性があります。一般的に小児期に発症するが、成人期まで続くこともあります。ADHDの患者は、注意を持続し、課題を達成し、活動を組織化し、衝動を制御することが困難です。ADHDの正確な原因は完全には解明されていないが、遺伝的、環境的、神経学的要因が関与していると考えられています。診断は通常、臨床評価と行動評価に依存します。治療には行動療法、薬物療法、生活習慣の調整などが含まれることが多く、症状の管理と生活の質の向上に役立ちます。

市場力学

ADHD（注意欠如・多動症）市場は、主に小児および成人のADHD診断有病率の上昇によって牽引されています。ADHDの症状に対する認識が高まり、理解が深まったことで、医療支援を求め、診断を受ける人が増えています。また、メンタルヘルス問題の受容が促進され、ADHDにまつわる偏見が減少したことも、市場の成長に寄与しています。さらに、医薬品治療の進歩や、効能が強化され副作用の少ない新薬が市場を押し上げています。ADHD患者のための行動療法や支援サービスの拡大は、医学的治療を補完し、包括的な市場成長を促進しています。さらに、ADHDの遺伝的・環境的要因の解明を目指した研究開発活動の活発化が、ADHD（注意欠如・多動症）市場を前進させています。しかし、偏見と誤診の問題は、今後数年間のADHD（注意欠如・多動症）市場の成長に課題する可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールはADHD（注意欠如・多動症）の世界市場における各セグメントを包括的に評価することもできます。ADHD（注意欠如・多動症）産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおけるADHD（注意欠如・多動症）市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートでは、著名な全地域にわたる個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 ADHD（注意欠如・多動症）-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 産業動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 ADHD（注意欠如・多動症）の世界市場分析：薬物タイプ別

  • 概要
  • 実績および予測データ分析
  • 精神刺激薬（アンフェタミン、メチルフェニデート、リスデキサムフェタミン、デクスメチルフェニデート）
  • 非精神刺激薬（アトモキセチン、グアンファシン、クロニジン、その他）

第6章 ADHD（注意欠如・多動症）の世界市場分析：デモグラフィック別

  • 概要
  • 実績および予測データ分析
  • 小児
  • 成人

第7章 ADHD（注意欠如・多動症）の世界市場分析：流通チャネル別

  • 概要
  • 実績および予測データ分析
  • 小売薬局
  • 病院薬局

第8章 ADHD（注意欠如・多動症）の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第9章 ADHD（注意欠如・多動症）企業の競合情勢

  • ADHD（注意欠如・多動症）市場競争
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Novartis AG
  • Eli Lilly And Company
  • Johnson & Johnson Services Inc.
  • Lupin
  • Takeda Pharmaceutical Company Limited
  • Mallinckrodt Plc.
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Aytu BioPharma Inc.（NEOS Therapeutics Inc.）
  • Supernus Pharmaceuticals Inc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Type (USD MN)
  • Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Market Sales By Geography (USD MN)
  • Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Market Sales By Geography (USD MN)
  • Analysis By Demographics (USD MN)
  • Children Market Sales By Geography (USD MN)
  • Adults Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Global Attention Deficit Hyperactivity Disorder Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Attention Deficit Hyperactivity Disorder Report
  • Market Research Process
  • Market Research Methodology
  • Global Attention Deficit Hyperactivity Disorder Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Type
  • Market Attractiveness Analysis By Demographics
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Type (USD MN)
  • Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Market Sales By Geography (USD MN)
  • Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Market Sales By Geography (USD MN)
  • Global Market Analysis By Demographics (USD MN)
  • Children Market Sales By Geography (USD MN)
  • Adults Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114726

The global demand for Attention Deficit Hyperactivity Disorder Market is presumed to reach the market size of nearly USD 28 Billion by 2032 from USD 19.32 Billion in 2023 with a CAGR of 4.21% under the study period 2024-2032.

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition featuring symptoms of hyperactivity, inattention, and impulsivity, which can disrupt daily functioning. It commonly presents in childhood but can continue into adulthood. Individuals with ADHD find it challenging to sustain attention, accomplish tasks, organize activities, and regulate impulses. The exact cause of ADHD is not wholly understood but is believed to involve genetic, environmental, and neurological factors. Diagnosis typically relies on clinical evaluation and behavioral assessments. Treatment often includes behavioral therapy, medication, and lifestyle adjustments to help manage symptoms and improve quality of life.

MARKET DYNAMICS

The attention deficit hyperactivity disorder (ADHD) market is primarily driven by the rising prevalence of ADHD diagnoses among children and adults. Increased awareness and better understanding of ADHD symptoms have led to more individuals seeking medical help and receiving diagnoses. The spurring acceptance of mental health issues and the reduction of stigma surrounding ADHD have also contributed to market growth. Furthermore, advancements in pharmaceutical treatments and new medications with enhanced efficacy and fewer side effects have boosted the market. Expanding behavioral therapies and support services for ADHD patients complements medical treatments, driving comprehensive market growth. Additionally, increasing research & development activities aimed at understanding the genetic and environmental factors of ADHD are propelling the attention deficit hyperactivity disorder market forward. However, stigma and misdiagnosis issues may challenge the attention deficit hyperactivity disorder market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Attention Deficit Hyperactivity Disorder. The growth and trends of Attention Deficit Hyperactivity Disorder industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Attention Deficit Hyperactivity Disorder market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

  • Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate)
  • Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others)

By Demographics

  • Children
  • Adults

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Attention Deficit Hyperactivity Disorder market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Attention Deficit Hyperactivity Disorder market include Novartis AG, Eli Lilly And Company, Johnson & Johnson Services Inc., Lupin, Takeda Pharmaceutical Company Limited, Mallinckrodt Plc., Pfizer Inc., Purdue Pharma L.P., Aytu BioPharma Inc. (NEOS Therapeutics Inc.), Supernus Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ATTENTION DEFICIT HYPERACTIVITY DISORDER - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Demographics
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DRUG TYPE

  • 5.1. Overview By Drug Type
  • 5.2. Historical and Forecast Data Analysis By Drug Type
  • 5.3. Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Historic and Forecast Sales By Regions
  • 5.4. Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Historic and Forecast Sales By Regions

6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DEMOGRAPHICS

  • 6.1. Overview By Demographics
  • 6.2. Historical and Forecast Data Analysis By Demographics
  • 6.3. Children Historic and Forecast Sales By Regions
  • 6.4. Adults Historic and Forecast Sales By Regions

7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data Analysis By Distribution Channel
  • 7.3. Retail Pharmacy Historic and Forecast Sales By Regions
  • 7.4. Hospital Pharmacy Historic and Forecast Sales By Regions

8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ATTENTION DEFICIT HYPERACTIVITY DISORDER COMPANIES

  • 9.1. Attention Deficit Hyperactivity Disorder Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF ATTENTION DEFICIT HYPERACTIVITY DISORDER INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Novartis AG
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Eli Lilly And Company
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Johnson & Johnson Services Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Lupin
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Takeda Pharmaceutical Company Limited
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Mallinckrodt Plc.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Pfizer Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Purdue Pharma L.P.
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Aytu BioPharma Inc. (NEOS Therapeutics Inc.)
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Supernus Pharmaceuticals Inc
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies